Top Markets
#1 Helium Helium +47.69%
#2 Pons Pons +37.87%
#3 TENDIES TENDIES +29.66%
#4 pipedog pipedog +22.25%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.17%
#7 Bounce Bounce +17.41%
#8 Songbird Songbird +12.58%
#9 Glidr Glidr +11.83%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +10.69%
Coin of the day
Helium Helium
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Kedudukan dalam Saham #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Harga Saham
$9.50
Disegerakkan terakhir: 2025-01-08
Modal Pasaran
$819.52M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Poseida Therapeutics, Inc. (PSTX)

Kategori

Healthcare
Pendapatan untuk Poseida Therapeutics, Inc. (PSTX)
Pendapatan pada Sep 2024 TTM: $-60.72M
Menurut laporan kewangan terkini Poseida Therapeutics, Inc., pendapatan semasa syarikat ialah $-60.72M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-63.46M, penurunan berbanding pendapatan pada tahun 2021 yang berjumlah $-124.97K. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Poseida Therapeutics, Inc. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-60.72M -50.77%
2023 $-123.32M 94.34%
2022 $-63.46M 50,676.96%
2021 $-124.97K -3.70%
2020 $-129.78K -99.85%
2019 $-86.53M 93.98%
2018 $-44.61M 120.94%
2017 $-20.19M 278.07%
2016 $-5.34M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -8,787.83%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,312.74%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 6,514.73%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 4,984.33%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH